BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

PURPOSE: Resistance to third-generation EGFR inhibitors including osimertinib arises in part from the C797S mutation in EGFR. Currently, no targeted treatment option is available for these patients. We have developed a new EGFR tyrosine kinase inhibitor (TKI), BBT-176, targeting the C797S mutation....

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Fujino, Toshio, Kim, Chulwon, Lee, Gwanghee, Lee, Yong-Hee, Kim, Dong-Wan, Ahn, Jin Seok, Mitsudomi, Tetsuya, Jin, Taiguang, Lee, Sang-Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425724/
https://www.ncbi.nlm.nih.gov/pubmed/37249619
http://dx.doi.org/10.1158/1078-0432.CCR-22-3901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425724/
https://www.ncbi.nlm.nih.gov/pubmed/37249619
http://dx.doi.org/10.1158/1078-0432.CCR-22-3901

Ejemplares similares